Claude Leclerc

USPTO Granted Patents = 25 (Patent Applications = 8)

CIPO Patents = 4

EPO Patents = 13 (Patent Applications = 8)

Average Co-Inventor Count = 4.1

ph-index = 6

Forward Citations = 235(Granted Patents)

Company Filing History:

Centre National De La Recherche Scientifique

patents

8 out of 1,743

Institut National De La Sante Et De La Recherche Medicale

Institute of Microbiology of the Ascr, V.v.i.

patents

6. 2 out of 2

Institute of Physiology of the Ascr, V.v.i.

patents

7. 1 out of 525

Ludwig Institute for Cancer Research Limited

patents

8. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1996-2021

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10899799 - Method for preparing multiple antigen glycopeptide carbohydrate conjugates (2021-01-26),

2. 10004794 - Vectors for molecule delivery to CD11b expressing cells (2018-06-26),

3. 9957301 - Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response (2018-05-01),

4. 9708596 - Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell (2017-07-18),

5. 9657074 - Enzymatic large-scale synthesis of mucin glyconjugates, and immunogenic applications thereof (2017-05-23),

6. 9410139 - [object Object] (2016-08-09),

7. 9387243 - Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof (2016-07-12),

8. 9370564 - Vectors for molecule delivery to CD11b expressing cells (2016-06-21),

9. 9222143 - Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell (2015-12-29),

10. 9095537 - Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response (2015-08-04),

11. 8747866 - [object Object] (2014-06-10),

12. 8637039 - Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof (2014-01-28),

13. 8628779 - Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof. therapeutic uses thereof (2014-01-14),

14. 8398991 - [object Object] (2013-03-19),

15. 8017132 - Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell (2011-09-13),

Title: Innovations of Claude Leclerc: A Pioneer in Glycopeptide Conjugates

Introduction: Claude Leclerc is a renowned inventor based in Paris, France, known for his significant contributions in the field of biotechnology. With an impressive portfolio of 25 patents, he has made substantial strides in developing novel methods and vectors for molecular delivery. His work not only showcases his inventive spirit but also his dedication to advancing medical science.

Latest Patents: Among his most recent patents is a method for preparing multiple antigen glycopeptide carbohydrate conjugates. This invention presents a sophisticated technique for creating carbohydrate T cell epitope conjugates, which have implications in vaccine development. Another significant patent involves vectors for molecule delivery to CD11b expressing cells, where he introduces an innovative use of adenylcyclase toxin. This invention aims to target specific in vivo molecules, enhancing the efficiency of immunogenic compositions and pharmaceutical applications.

Career Highlights: Throughout his career, Claude has held influential positions in prestigious research institutions, including the Institut Pasteur and the Centre National de la Recherche Scientifique. His work at these organizations has propelled forward numerous research initiatives that bridge science and innovation.

Collaborations: Collaboration has been an integral part of Claude’s journey. He has worked alongside notable scientists such as Daniel Ladant and Peter Sebo, contributing to a collaborative environment that fosters innovation and creativity in research.

Conclusion: Claude Leclerc stands out as a beacon of innovation within the realm of biotechnological inventions. His latest patents reflect his commitment to developing new methodologies and solutions that could potentially transform therapeutic approaches in medicine. His ongoing contributions continue to inspire future research and innovation within the scientific community.

This text is generated by artificial intelligence and may not be accurate.